Effects of ChemotherapyPhase 2/3NCT00911352
Cryotherapy Intervention for Docetaxel-induced Nail Toxicities
A Phase 2/3 study testing Frozen gel glove (Elasto-Gel Mitten) in people with Effects of Chemotherapy, run by Princess Alexandra Hospital, Brisbane, Australia at 1 site in Australia.
Trial summary
Between 30% and 88% of chemotherapy patients receiving docetaxel experience side effects of the hand ranging from skin and nail disfigurement, blistering, desquamation, pain, infection, and impaired treatment-related quality of life and function. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Effects of Chemotherapy
- What is being tested?
- Frozen gel glove (Elasto-Gel Mitten)
- Type of treatment
- Injection or infusion, Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 65 participants
- Where
- 1 siteAustralia
- Study dates
- Oct 2010to Dec 2012
- Phase
- Phase 2/3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- patients receiving docetaxel as mono- or combination therapy
- patients with no nail disorders at the start of treatment
- life expectancy of at least 3 months
Who cannot join
- patients previously treated with taxane chemotherapy
- Raynaud's phenomenon
- distal metastases
- ungual pathology
- arteriopathy
- cold intolerance
- peripheral neuropathy of grade 2 or higher
- patients currently enrolled in clinical trials
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Nurse-initiated Cryotherapy Intervention for Docetaxel-induced Nail Toxicities: Case-control Study
Between 30% and 88% of chemotherapy patients receiving docetaxel experience side effects of the hand ranging from skin and nail disfigurement, blistering, desquamation, pain, infection, and impaired treatment-related quality of life and function. Preliminary data indicate that nurse-initiated cryotherapy during treatment may lower the incidence and severity of these side effects, but several issues should be addressed before this intervention is implemented in hospital settings. These include more rigorous study design, larger sampling frames, and consideration of infection control concerns. This study will address these issues, thereby rigorously evaluating the safety and efficacy of nurse-initiated cryotherapy at Princess Alexandra Hospital.
Read the detailed description
Research problem:
Internationally, cryotherapy for docetaxel-induced nail and skin toxicities of the hand has become a popular primary treatment. Yet there is little evidence beyond one Phase II, non-randomised, (n=45) study to support such widespread use. There are also unanswered concerns relating to the potential of this treatment to cross-infect patients at risk of immunocompromise. This phase II case-control study extends previous work to address sample size concerns, enhance methodological rigour and add new evidence with respect to infection control, prior to its possible implementation at Princess Alexandra Hospital (PAH).
Hypothesis/questions/outcomes:
Aim: This study will investigate the utility, efficacy and safety of cryotherapy, in the form of frozen gel gloves, with respect to the prevention of docetaxel-induced nail and skin toxicities in cancer patients.
Hypotheses:
H1: Cryotherapy reduces the incidence and severity of docetaxel-induced nail and skin toxicities.
H2: Cryotherapy to prevent docetaxel-induced nail and skin toxicities is tolerated by cancer patients.
H3: A standardised decontamination protocol prevents healthcare-acquired infections potentially associated with cryotherapy.
Anticipated results: The primary endpoint is a decrease in the incidence and severity of nail and skin toxicities over the course of treatment, as measured by the CTCAE scores. Secondary endpoints include delayed time to occurrence of any nail or skin toxicity; patient comfort; and a successful glove decontamination protocol as evidenced by the absence of epidemiologically significant organisms on frozen gloves.
Research design:
Population and sampling: Approximately 300 new breast, prostate and lung cancer patients are diagnosed per year at PAH. Not all of these are treated with docetaxel, and some are placed on clinical trials, so will not be available for enrolment in the study. Data from PAH Human Information Management Services indicates that approximately 120 patients will therefore be eligible to enrol in the study. Accounting for a 50% rate of refusal or failure to meet the study criteria, it is anticipated that approximately 60 patients will enrol in the study in 12 months. This amounts to 60 control and 60 intervention hands for comparison.
Withdrawal criteria: severe cold intolerance or withdrawal of consent.
Procedure: Standard cryotherapy comprises a disposable cotton glove overlaid with a glycerine gel-filled glove, which cover the hand to the wrist and separate the thumb from the rest of the hand. The gel glove is frozen for at least 3 hours at -0.25 to -0.30°C prior to use. Each patient's hands will be randomly allocated to intervention or control. Each patient will wear the triple glove set on their intervention hand. No glove set will be used on the other hand, which acts as the case control. During each docetaxel infusion, the patient will wear the gloves for a total of 90 minutes (15 minutes before the administration of docetaxel, during the 1-hour docetaxel infusion, and 15 minutes after the end of infusion). This is a standard procedure during cryotherapy that will ensure the patients' peripheries are vasoconstricted on commencement of the infusion and for enough time afterwards to ensure circulating drug does not reach the target area. Because of the duration of the infusion, more than one gel glove will be used successively (for 45 minutes each) to maintain a consistently low temperature on the hand and nails. Using this method, the study will determine the comparative incidence of skin and nail disorders with and without cold protection.
The additional infection control measure in this study incorporates (1) insertion of a disposable surgical glove (which exceeds the length of the cotton and gel gloves) between the cotton and gel gloves to minimise the risk of cross-contamination and (2) surface decontamination using a standard cleaning protocol. The term 'cleaning' refers to the use of mechanical action, detergent and warm water, followed by rinsing and drying. It aims to remove organic matter, visible soils and salts from the glove surface. Cleaning removes the bulk of micro-organisms from surfaces and they are also unable to multiply on inanimate surfaces cleaned and dried in this manner. In accordance with the Spaulding Classification System the glove cleaning protocol will incorporate 1) cleaning all internal and external surfaces with neutral detergent and warm water; 2) rinsing with clean water; 3) cleaning all internal and external surfaces with a 70% alcohol-based solution; and 4) complete air drying of the glove.
Data collection: Patients receive docetaxel once every 21 days for 126 - 189 days (i.e. on 6 to 9 separate occasions each; docetaxel is administered on day 1 of each cycle). Nail and skin toxicity appear between days 36 to 72 in untreated patients, and increases in severity until the end of treatment2-6,8. Cryotherapy will commence on day 1; will occur every 21 days with docetaxel administration thereafter, and cease after the final dose of docetaxel. Patients' toxicities will be assessed independently prior to the commencement of each of the docetaxel infusions, and three-weekly thereafter, by 2 blinded clinical nurse assessors using the Common Toxicity Criteria for Adverse Events1. The assessors will be trained by a dermatologist in the rating of these toxicities prior to study commencement. The training will also establish inter-rater reliability ratings between assessors, using digital photographs of skin and nail toxicities already available from clinical trials records at Princess Alexandra Hospital. In addition to blinded in-clinic assessment, digital photography of each hand will be undertaken under standardised lighting conditions prior to the commencement of each infusion. This will enable the nurses' assessment to be regularly compared with the dermatologist's assessment to ensure inter-rater reliability.
Because the final infusion may also affect the nails beyond treatment cessation, nail assessment will also be undertaken 3 weeks after the last infusion during routine OPD follow-up. Patients' comfort level with cryotherapy will also be assessed during each of the infusions, using a 4-point rating system to determine whether patients are dissatisfied (0), not very satisfied (1), satisfied (2), or very satisfied (3) with the treatment in terms of glove contact, temperature tolerance and immobilisation constraints.
A pre-post assessment of the decontamination protocol of the gel glove at each of the treatment sessions will also be undertaken. Microbial Cultural and Sensitivity (MC\&S) and antibiograms will be undertaken on swabs taken from glove surfaces at T1 (pre-decontamination) and T2 (post- decontamination). Sites for swabbing of all gloves will be standardised to 1) the internal glove surface of the back of the hand; 2) the internal glove surface of the palm of the hand; 3) the internal glove surface at the tip of the second index finger; and 4) the internal glove surface at tip of the thumb. These sites are well-established as being problematic for cleaning and decontamination in hand hygiene, where carriage of microbial organisms is high31. MC\&S and antibiograms will test for non-multidrug-resistant Staphylococcus Aureus (nmMRSA); multidrug-resistant Staphylococcus Aureus (MRSA), and vancomycin-resistant Enterococcus, extended spectrum (VRE).
A client record form will record and update relevant demographic, disease- and treatment-related data at each time point.
Data analysis:
Analyses of skin and nail toxicity will replicate the method used in the original study, and will be undertaken on an intention-to-treat basis. Matched-pair t-tests will be used to determine the statistical significance of any differences in the incidence and severity of nail and skin toxicities between protected and unprotected hands. Because time-to-event endpoints will be used, Kaplan-Meier and log-rank methods will estimate differences in time to toxicity occurrence. The impact of nail and skin toxicity occurrence for confounders and covariates will be determined via multivariate Cox regression analyses. Frozen glove contamination will be analysed by determining frequencies and types of micro-organisms.
- Conditions
- Effects of Chemotherapy
- Being tested
- Frozen gel glove (Elasto-Gel Mitten)
- Keywords
- Cryotherapy, Hand toxicity, Nail toxicity, Infection control
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Frozen gel glove (Elasto-Gel Mitten)Device
Also called Elasto-Gel Mitten
Gel glove is frozen for > 3 hours at -5 to -30°C prior to use. Each patient wears a triple glove set (surgical glove overlaid with cotton glove, overlaid with gel glove) on their intervention hand. Gloves are worn for duration of infusion (15 mins pre, 60 minutes intratreatment and 15 mins post) to ensure the patients' peripheries are vasoconstricted on commencement of the infusion and for enough time afterwards to ensure circulating drug does not reach the target area. Because of the duration of the infusion, more than one gel glove will be used successively (for 45 minutes each) to maintain a consistently low temperature on the hand and nails.
| Study group | Role | What they receive |
|---|---|---|
| Frozen gel glove (Elasto-Gel Mitten) | Experimental | Cryotherapy hand Receives: Device: Frozen gel glove (Elasto-Gel Mitten) |
| No frozen glove therapy | No intervention | Usual care |
What is being measured
The primary outcome is the main question the study is designed to answer.
Differences in the incidence and severity of nail and skin toxicities between protected and unprotected hands
Measured: 12 months
Secondary outcomes (2)
Safety and tolerability of frozen glove treatment
Measured: 12 months
Adequacy of infection control measure added to glove protocol
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Jun 2009 (estimated)
- Study startOct 2010
- Primary completionDec 2012
- Study completionDec 2012
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Effects of ChemotherapyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2/3
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 65 participants (actual)
Sponsor and investigators
- Lead sponsor
- Princess Alexandra Hospital, Brisbane, Australia
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Alexandra McCarthy, Princess Alexandra Hospital, Brisbane, Australia
- Investigators
- Alexandra McCarthy, PhD, Principal investigator, Queensland University of Technology
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00911352
- Sponsor's protocol ID
- 2009/043
- Status last verified
- Dec 2012
- First submitted
- 29 May 2009
- Last updated
- 5 Dec 2012
- Results posted
- No
- Data monitoring committee
- No
Publications
McCarthy AL, Shaban RZ, Gillespie K, Vick J. Cryotherapy for docetaxel-induced hand and nail toxicity: randomised control trial. Support Care Cancer. 2014 May;22(5):1375-83. doi: 10.1007/s00520-013-2095-x. Epub 2013 Dec 22.
PubMed 24362908
Study at a glance
From the registry record, last updated by the sponsor on 5 Dec 2012. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Nurse-initiated Cryotherapy Intervention for Docetaxel-induced Nail Toxicities: Case-control Study
- ClinicalTrials.gov ID
- NCT00911352
- Acronym / sponsor ID
- 2009/043
- Conditions
- Effects of Chemotherapy
- Keywords
- Cryotherapy, Hand toxicity, Nail toxicity, Infection control
- Phase
- Phase 2/3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 65 participants (actual)
- Lead sponsor
- Princess Alexandra Hospital, Brisbane, AustraliaUniversity, hospital or other
- Study start
- Oct 2010
- Primary completion
- Dec 2012 (actual)
- Study completion
- Dec 2012 (actual)
- First posted
- 1 Jun 2009 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Between 30% and 88% of chemotherapy patients receiving docetaxel experience side effects of the hand ranging from skin and nail disfigurement, blistering, desquamation, pain, infection, and impaired treatment-related quality of life and function. Preliminary data indicate that nurse-initiated cryotherapy during treatment may lower the incidence and severity of these side effects, but several issues should be addressed before this intervention is implemented in hospital settings. These include more rigorous study design, larger sampling frames, and consideration of infection control concerns. This study will address these issues, thereby rigorously evaluating the safety and efficacy of nurse-initiated cryotherapy at Princess Alexandra Hospital.
Detailed description
Research problem:
Internationally, cryotherapy for docetaxel-induced nail and skin toxicities of the hand has become a popular primary treatment. Yet there is little evidence beyond one Phase II, non-randomised, (n=45) study to support such widespread use. There are also unanswered concerns relating to the potential of this treatment to cross-infect patients at risk of immunocompromise. This phase II case-control study extends previous work to address sample size concerns, enhance methodological rigour and add new evidence with respect to infection control, prior to its possible implementation at Princess Alexandra Hospital (PAH).
Hypothesis/questions/outcomes:
Aim: This study will investigate the utility, efficacy and safety of cryotherapy, in the form of frozen gel gloves, with respect to the prevention of docetaxel-induced nail and skin toxicities in cancer patients.
Hypotheses:
H1: Cryotherapy reduces the incidence and severity of docetaxel-induced nail and skin toxicities.
H2: Cryotherapy to prevent docetaxel-induced nail and skin toxicities is tolerated by cancer patients.
H3: A standardised decontamination protocol prevents healthcare-acquired infections potentially associated with cryotherapy.
Anticipated results: The primary endpoint is a decrease in the incidence and severity of nail and skin toxicities over the course of treatment, as measured by the CTCAE scores. Secondary endpoints include delayed time to occurrence of any nail or skin toxicity; patient comfort; and a successful glove decontamination protocol as evidenced by the absence of epidemiologically significant organisms on frozen gloves.
Research design:
Population and sampling: Approximately 300 new breast, prostate and lung cancer patients are diagnosed per year at PAH. Not all of these are treated with docetaxel, and some are placed on clinical trials, so will not be available for enrolment in the study. Data from PAH Human Information Management Services indicates that approximately 120 patients will therefore be eligible to enrol in the study. Accounting for a 50% rate of refusal or failure to meet the study criteria, it is anticipated that approximately 60 patients will enrol in the study in 12 months. This amounts to 60 control and 60 intervention hands for comparison.
Withdrawal criteria: severe cold intolerance or withdrawal of consent.
Procedure: Standard cryotherapy comprises a disposable cotton glove overlaid with a glycerine gel-filled glove, which cover the hand to the wrist and separate the thumb from the rest of the hand. The gel glove is frozen for at least 3 hours at -0.25 to -0.30°C prior to use. Each patient's hands will be randomly allocated to intervention or control. Each patient will wear the triple glove set on their intervention hand. No glove set will be used on the other hand, which acts as the case control. During each docetaxel infusion, the patient will wear the gloves for a total of 90 minutes (15 minutes before the administration of docetaxel, during the 1-hour docetaxel infusion, and 15 minutes after the end of infusion). This is a standard procedure during cryotherapy that will ensure the patients' peripheries are vasoconstricted on commencement of the infusion and for enough time afterwards to ensure circulating drug does not reach the target area. Because of the duration of the infusion, more than one gel glove will be used successively (for 45 minutes each) to maintain a consistently low temperature on the hand and nails. Using this method, the study will determine the comparative incidence of skin and nail disorders with and without cold protection.
The additional infection control measure in this study incorporates (1) insertion of a disposable surgical glove (which exceeds the length of the cotton and gel gloves) between the cotton and gel gloves to minimise the risk of cross-contamination and (2) surface decontamination using a standard cleaning protocol. The term 'cleaning' refers to the use of mechanical action, detergent and warm water, followed by rinsing and drying. It aims to remove organic matter, visible soils and salts from the glove surface. Cleaning removes the bulk of micro-organisms from surfaces and they are also unable to multiply on inanimate surfaces cleaned and dried in this manner. In accordance with the Spaulding Classification System the glove cleaning protocol will incorporate 1) cleaning all internal and external surfaces with neutral detergent and warm water; 2) rinsing with clean water; 3) cleaning all internal and external surfaces with a 70% alcohol-based solution; and 4) complete air drying of the glove.
Data collection: Patients receive docetaxel once every 21 days for 126 - 189 days (i.e. on 6 to 9 separate occasions each; docetaxel is administered on day 1 of each cycle). Nail and skin toxicity appear between days 36 to 72 in untreated patients, and increases in severity until the end of treatment2-6,8. Cryotherapy will commence on day 1; will occur every 21 days with docetaxel administration thereafter, and cease after the final dose of docetaxel. Patients' toxicities will be assessed independently prior to the commencement of each of the docetaxel infusions, and three-weekly thereafter, by 2 blinded clinical nurse assessors using the Common Toxicity Criteria for Adverse Events1. The assessors will be trained by a dermatologist in the rating of these toxicities prior to study commencement. The training will also establish inter-rater reliability ratings between assessors, using digital photographs of skin and nail toxicities already available from clinical trials records at Princess Alexandra Hospital. In addition to blinded in-clinic assessment, digital photography of each hand will be undertaken under standardised lighting conditions prior to the commencement of each infusion. This will enable the nurses' assessment to be regularly compared with the dermatologist's assessment to ensure inter-rater reliability.
Because the final infusion may also affect the nails beyond treatment cessation, nail assessment will also be undertaken 3 weeks after the last infusion during routine OPD follow-up. Patients' comfort level with cryotherapy will also be assessed during each of the infusions, using a 4-point rating system to determine whether patients are dissatisfied (0), not very satisfied (1), satisfied (2), or very satisfied (3) with the treatment in terms of glove contact, temperature tolerance and immobilisation constraints.
A pre-post assessment of the decontamination protocol of the gel glove at each of the treatment sessions will also be undertaken. Microbial Cultural and Sensitivity (MC\&S) and antibiograms will be undertaken on swabs taken from glove surfaces at T1 (pre-decontamination) and T2 (post- decontamination). Sites for swabbing of all gloves will be standardised to 1) the internal glove surface of the back of the hand; 2) the internal glove surface of the palm of the hand; 3) the internal glove surface at the tip of the second index finger; and 4) the internal glove surface at tip of the thumb. These sites are well-established as being problematic for cleaning and decontamination in hand hygiene, where carriage of microbial organisms is high31. MC\&S and antibiograms will test for non-multidrug-resistant Staphylococcus Aureus (nmMRSA); multidrug-resistant Staphylococcus Aureus (MRSA), and vancomycin-resistant Enterococcus, extended spectrum (VRE).
A client record form will record and update relevant demographic, disease- and treatment-related data at each time point.
Data analysis:
Analyses of skin and nail toxicity will replicate the method used in the original study, and will be undertaken on an intention-to-treat basis. Matched-pair t-tests will be used to determine the statistical significance of any differences in the incidence and severity of nail and skin toxicities between protected and unprotected hands. Because time-to-event endpoints will be used, Kaplan-Meier and log-rank methods will estimate differences in time to toxicity occurrence. The impact of nail and skin toxicity occurrence for confounders and covariates will be determined via multivariate Cox regression analyses. Frozen glove contamination will be analysed by determining frequencies and types of micro-organisms.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Frozen gel glove (Elasto-Gel Mitten) | Experimental | Device: Frozen gel glove (Elasto-Gel Mitten)Cryotherapy hand |
| No frozen glove therapy | No intervention | –Usual care |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- patients receiving docetaxel as mono- or combination therapy
- patients with no nail disorders at the start of treatment
- life expectancy of at least 3 months
Key exclusion criteria (8 listed)
- patients previously treated with taxane chemotherapy
- Raynaud's phenomenon
- distal metastases
- ungual pathology
- arteriopathy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Frozen gel glove (Elasto-Gel Mitten)Also: Elasto-Gel MittenGel glove is frozen for > 3 hours at -5 to -30°C prior to use. Each patient wears a triple glove set (surgical glove overlaid with cotton glove, overlaid with gel glove) on their intervention hand. Gloves are worn for duration of infusion (15 mins pre, 60 minutes intratreatment and 15 mins post) to ensure the patients' peripheries are vasoconstricted on commencement of the infusion and for enough time afterwards to ensure circulating drug does not reach the target area. Because of the duration of the infusion, more than one gel glove will be used successively (for 45 minutes each) to maintain a consistently low temperature on the hand and nails. | Device | Frozen gel glove (Elasto-Gel Mitten) |
Primary outcome
Differences in the incidence and severity of nail and skin toxicities between protected and unprotected hands
Time frame: 12 months
2 secondary outcomes
Safety and tolerability of frozen glove treatment
Time frame: 12 months
Adequacy of infection control measure added to glove protocol
Time frame: 12 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Dec 2012.
- Derived from this study: PubMed 24362908McCarthy AL, Shaban RZ, Gillespie K, Vick J. Cryotherapy for docetaxel-induced hand and nail toxicity: randomised control trial. Support Care Cancer. 2014 May;22(5):1375-83. doi: 10.1007/s00520-013-2095-x. Epub 2013 Dec 22.
Related trials for Effects of Chemotherapy
Recruiting
Effect of Pecha Kucha-Based Education on Symptom Management and Quality of Life in Patients Receiving Chemotherapy
Cancer, Neoplams
Not yet recruiting
The Effect of Aerobic and Resistance Training With and Without Neurodynamic Exercises on Chemotherapy-induced Peripheral Neuropathy Symptoms and Associated Neuro-immune Mechanisms
Chemotherapy Induced Peripheral Neuropathy (CIPN)
Not yet recruitingPhase 3
Clinical Study of DA-007 for the Treatment of Chemotherapy Induced Alopecia
Chemotherapy Induced Alopecia, Chemotherapy Side Effects
RecruitingPhase 3
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Breast Neoplasms
Recruiting
More Than Just X-Rays - Imaging of Chemotherapy-induced Morphological and Functional Cardiovascular and Lung Changes After Childhood ALL and Other Cancers - a Monocentric Late Effects Study (MaximALL)
Acute Lymphatic Leukemia, Lymphoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Alexandra McCarthy, PhD principal investigator
Queensland University of Technology
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2/3 study testing Frozen gel glove (Elasto-Gel Mitten) in people with Effects of Chemotherapy, run by Princess Alexandra Hospital, Brisbane, Australia at 1 site in Australia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 5 Dec 2012. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Australia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Differences in the incidence and severity of nail and skin toxicities between protected and unprotected hands (time frame: 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00911352, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Dec 2012.